Enovis Corporation

Ladies and gentlemen, thank you for standing by and welcome to the ANOVA second quarter 2022 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, then the number one on your telephone keypad. To withdraw your question, simply press star one again. I would now like to turn the call over to Derek Lekow. Please go ahead, sir.

Thank you, Paula. Good morning, everyone. Thank you for joining us today for our second quarter results conference call. I'm Derek Lekow, Vice President of Investor Relations. Joining me on the call today are Matt Trutola, CEO, Chris Hicks, Executive Vice President and CFO. And also joining us this morning for a quick introduction before we get to the prepared remarks and Q&A is Ben Barry, We previously announced we'll serve as Inovus' CFO when Chris retires at the end of the year. Our earnings release was issued earlier this morning and is available in the investor section of our website, inovus.com. We'll be using a slide presentation to walk you through today's call, which can also be found on our website. Both the audio and slide presentation of this call will be archived on the website later today and will be available until the next quarterly conference call. During this call, we'll be making some forward-looking statements about our beliefs and estimates regarding future events and results. These forward-looking statements are subject to risks and uncertainties, including those set forth in the Safe Harbor language in today's earnings release and in our filings with the SEC. Actual results may differ materially from any forward-looking statements that we make today. The forward-looking statements speak only as of today, and we do not assume any obligation or intent to update them, except as required by law. With respect to any non-GAAP financial measures referenced during the call today, the accompanying reconciliation information relating to those measures can be found in our press release and in the appendix of today's slide presentation. You will note that we have provided reconciliation tables for each of the 2021 quarterly historical results on an adjusted standalone basis for comparability. With that, let me turn it over to Matt for some opening remarks, and then we will start the earnings presentation. Matt?

Thank you, Derek. About a month ago, we announced our planned transition for the Inovus CFO role, which will culminate in Chris's retirement at the end of the year and Ben taking on the role. After his retirement, Chris will remain with us in an advisory capacity through 2023 to ensure a smooth transition. Chris was one of my first hires after I joined the company as CEO back in 2015. His leadership has been pivotal to our operating improvements and to our strategic transformation to a pure play med tech company. He also raised the bar for the global finance function and attracted great talent like Ben, which strengthened the capabilities of the team. He had been considering his retirement path for a while, and I know that he's looking forward to spending more time with his family and friends and pursuing other passions. Ben joined us in early 2020 as the CFO of our MedTech segment after many years of finance leadership experience in the sector. We've been impressed with how quickly he's learned the business and immediately rose to the COVID challenges that emerged as he walked in the door. Ben has made a meaningful impact to our operational performance and growth strategy in a short time, and he's a strong leader with high integrity, and I'm confident that he'll build on the strong foundation that Chris has established. I look forward to working with Ben as we establish Inovus as a high-performing MedTech company. You'll get to know Ben more in the coming quarters. I've asked him to briefly introduce himself on this call. Ben?